L-Carnitine for Fatigue in COPD

Overview

About this study

We hypothesize that supplementation with L-carnitine that is available both as an FDA-approved therapy for primary carnitine deficiency, as well as widely available as an over-the-counter ergogenic aid will improve wellbeing and function measured by questionnaires in patient with chronic obstructive pulmonary disease (COPD). We further hypothesize based on our review of literature that addition of health coaching (HC) to L-carnitine will yield greater gains.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • COPD patients with a positive screen for fatigue

Exclusion Criteria:

  • Vulnerable population - pregnant women, prisoners, unable to provide consent
  • Pre-menopausal/breastfeeding women (pregnancy category B)
  • Thyroid disease
  • Anticoagulation therapy
  • Decompensated cardiac disease
  • Chronic Kidney Disease (CKD4 or above)
  • Known seizure disorder
  • Active malignancy
  • Exacerbation of underlying pulmonary disease or acute illness in the 6 weeks before screening
  • Enrollment in the past 6 weeks or currently in a cardiac or pulmonary rehab program or other physical fitness class(es).
  • Difficulty with swallowing pills

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Roberto Benzo, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available
.
CLS-20266947

Mayo Clinic Footer